Icon Plc

ICLR

ICLR is a global provider of outsourced clinical development services to the pharmaceutical, biotechnology, and medical device industries.
It is a leading contract research organization (CRO) known for its comprehensive service offerings and deep therapeutic expertise.

$108.14 +2.01 (+1.89%)

Updated: February 27, 2026, 16:00 EST

Analyzed by Rockflow Bobby Quantitative Model āœ“ Updated Daily

Investment Opinion: Should I buy ICLR Today?

Based on the provided analysis, ICLR presents a very high-risk profile with significant challenges across multiple fronts.

From a technical perspective, the stock is severely damaged, having plummeted over 43% in one month. While this suggests it may be oversold, the relentless selling pressure indicates a clear lack of buyer confidence. Fundamentally, the company's health is deeply concerning. A net profit margin collapse to 0.1% and an effective tax rate of 93.8% point to severe earnings quality issues. Valuation metrics are alarming, with a forward P/E over 1,400 signaling extreme market pessimism about future profitability, making the stock nearly impossible to value reliably. Risks are elevated, highlighted by a beta of 1.29 and a maximum drawdown of over -60% in the past year.

Investment Recommendation:

Given the confluence of severe technical weakness, a fundamental breakdown in profitability, and exceptionally pessimistic forward earnings projections, ICLR is not a compelling investment at this time. The extreme valuation metrics suggest the market is pricing in significant further deterioration. While the stock may see short-term bounces from oversold conditions, the underlying operational and financial headwinds present too much risk for most investors. A cautious approach is warranted until there are clear signs of a fundamental turnaround.

*This is not investment advice, for reference only.*

CTA Banner

ICLR 12-Month Price Forecast

RockFlow Model Forecast: Three Scenarios for 2026

Based on the comprehensive analysis, the 12-month outlook for ICLR is highly pessimistic. The primary catalysts for any potential recovery would be a drastic operational turnaround, such as a significant restructuring that restores profitability and sharply reduces its effective tax rate, but evidence of this is currently lacking. The risks are substantial and include the continuation of severe earnings pressure, a complete loss of investor confidence, and the possibility of further significant price declines given the extreme valuation metrics and negative momentum. In the absence of a credible turnaround plan, the stock faces the risk of testing materially lower price levels, likely well below the current $104.77.

*This is not investment advice, for reference only.*

Wall Street Consensus

Most Wall Street analysts are optimistic about Icon Plc's 12-month outlook, with consensus target around $108.14, indicating expected upside potential.

Average Target
$108.14
21 analysts
Implied Upside
+0%
vs. current price
Analyst Count
21
covering this stock
Price Range
$87 - $141
Analyst target range
Buy Buy
10 (48%)
Hold Hold
10 (48%)
Sell Sell
1 (5%)

Bulls vs Bears: ICLR Investment Factors

Overall, ICLR has investment potential but also faces challenges. Here are key factors to weigh before investing.

Bullish Bullish
  • Price Target Increase: Barclays raised Icon's price target from $185 to $200.
  • Investment Firm Acquisition: Muhlenkamp & Co. purchased a new stake of 73,467 shares.
  • Industry Leadership Recognition: Polen Capital highlighted the company's recovery from challenges.
  • Market Problem Identification: Survey highlights delays, positioning Icon as a solution provider.
Bearish Bearish
  • Multiple Legal Investigations: Several law firms are investigating potential securities law violations.
  • Shareholder Fraud Allegations: Schall Law Firm is investigating fraud claims against the company.
  • Investor Loss Notification: Law firms are actively contacting investors who suffered losses.
Reward Banner

ICLR Technical Analysis

ICLR has experienced substantial underperformance with a dramatic price decline over the past year, characterized by extreme volatility and significant losses.

The stock shows severe weakness in the short term, plunging over 43% in one month and 36% over three months, markedly underperforming the market by nearly 40%. This sharp descent indicates sustained and aggressive selling pressure.

Currently trading approximately midway between its 52-week high and low, the extreme recent volatility suggests the stock is likely in an oversold condition following such a precipitous drop, though significant technical damage persists.

šŸ“Š Beta
1.29
1.29x market volatility
šŸ“‰ Max Drawdown
-60.5%
Largest decline past year
šŸ“ˆ 52-Week Range
$67-$211
Price range past year
šŸ’¹ Annual Return
-43.1%
Cumulative gain past year
Period ICLR Return S&P 500
1m -42.0% -1.4%
3m -34.3% +4.1%
6m -40.0% +7.5%
1y -43.1% +15.4%
ytd -42.7% +0.4%

ICLR Fundamental Analysis

Revenue & Profitability ICLR's Q3 2025 revenue grew modestly to $2.04 billion from $2.02 billion in Q2, but profitability weakened significantly, with net profit margin plummeting from 9.1% to just 0.1%. This sharp decline was driven by elevated other expenses and a high effective tax rate of 93.8%, compressing bottom-line results despite stable operating margins.

Financial Health The company maintains a conservative capital structure with a low debt ratio of 21.6% and manageable debt-to-equity of 0.38, though the cash ratio of 0.15 indicates modest liquidity buffers. Operating cash flow coverage appears adequate, but the cash flow-to-debt ratio of 0.11 suggests limited flexibility for additional leverage or unexpected demands.

Operational Efficiency Operational metrics show strain, with ROE dropping to near zero (0.03%) and asset turnover remaining low at 0.12, indicating suboptimal utilization of capital. The extended cash conversion cycle of 117 days, driven by high days sales outstanding, points to working capital inefficiencies that are weighing on overall returns.

Quarterly Revenue
$2.0B
2025-09
Revenue YoY Growth
+0.6%
YoY Comparison
Gross Margin
22.3%
Latest Quarter
Free Cash Flow
$1.0B
Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

RockFlow Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

Try Now & Get Tesla Stock Reward

Valuation Analysis: Is ICLR Overvalued?

Based on the valuation metrics provided, ICLR presents a highly unusual and concerning valuation profile. The trailing PE ratio of 14.12 appears reasonable, but it is completely disconnected from the astronomical forward PE of over 1,437 and a negative PEG ratio of -14.57. The forward PE suggests extreme market pessimism about near-term earnings collapsing, while the negative PEG and exceptionally high EV/EBITDA of 89.08 indicate that the company is expected to have declining earnings growth, making traditional PE-based valuation largely unreliable for this stock.

Given the unavailability of specific industry average data, a precise peer comparison cannot be conducted. However, the extreme disparity between the TTM and forward PE ratios, combined with a negative PEG, strongly suggests that ICLR's valuation is an outlier. These metrics typically signal that the company is facing significant fundamental challenges that are not reflected in its past earnings, placing it in a precarious position relative to most profitable enterprises, even without direct industry benchmarks.

PE
14.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -56Ɨ-1437Ɨ
vs. Industry Avg
N/A
Industry PE ~N/AƗ
EV/EBITDA
89.1x
Enterprise Value Multiple

Investment Risk Disclosure

Volatility Risk: With a beta of 1.287, ICLR is expected to be approximately 29% more volatile than the broader market, indicating significant exposure to market fluctuations. The exceptionally steep maximum drawdown of -60.54% over the past year underscores a severe historical price decline, suggesting high downside volatility and substantial loss potential for investors. This combination points to elevated volatility risk, particularly in adverse market conditions.

Other Risks: The apparent absence of short interest is generally a positive factor, implying a lack of significant negative market sentiment or aggressive speculative betting against the stock. However, while this reduces risks associated with short squeezes, investors should still assess other liquidity metrics and company-specific factors such as earnings visibility, competitive pressures, or regulatory changes that could affect the stock's stability.

FAQs

Is ICLR a good stock to buy?

Bearish. ICLR faces severe profitability erosion (net margin collapse to 0.1%), a deeply concerning valuation (forward P/E >1,400 signaling extreme earnings pessimism), and significant legal overhangs from fraud investigations. This stock is only suitable for highly risk-tolerant, speculative investors willing to bet on a potential turnaround amid substantial uncertainty.

Is ICLR stock overvalued or undervalued?

Based on the metrics provided, ICLR appears to be overvalued.

The current valuation is not supported by fundamentals but seems to rely purely on past performance. While the trailing P/E of 14.12 looks reasonable, it is completely disconnected from reality. The astronomical forward P/E of over 1,400 and a negative PEG ratio (-14.57) imply the market expects catastrophic earnings collapse. The high PS ratio (6.63) is also concerning given the company's near-zero profitability and operational inefficiencies.

The primary reasons for this overvaluation are the severe deterioration in profitability (net margin collapsing to 0.1%) and weak operational metrics (low ROE, asset turnover). The stock price has not yet adjusted to reflect these severe fundamental challenges.

What are the main risks of holding ICLR?

Based on the provided information, here are the key risks of holding ICLR, ordered by importance:

1. Severe Profitability Collapse: The net profit margin plummeted to just 0.1% due to a crippling effective tax rate and high other expenses, indicating a fundamental breakdown in bottom-line performance. 2. Extreme Price Volatility and Downside Risk: The stock's 43% one-month plunge and a maximum drawdown of over -60% highlight severe selling pressure and substantial historical loss potential for investors. 3. Operational Inefficiency and Poor Capital Utilization: A near-zero Return on Equity (ROE) and a very low asset turnover ratio of 0.12 signal significant strain in generating profits from invested capital and assets. 4. Working Capital Management Strain: An extended cash conversion cycle of 117 days, driven by high days sales outstanding, points to inefficiencies in collecting receivables that tie up cash and hurt liquidity.

What is the price forecast for ICLR in 2026?

Based on the provided analysis, ICLR's forecast through 2026 is highly challenging.

1. Target Price Range: * Base Case: $50 - $70, reflecting a continuation of severe operational and profitability issues. * Bull Case: $110 - $130, contingent on a successful and credible corporate restructuring that dramatically improves margins.

2. Key Growth Drivers: * A credible operational turnaround plan that significantly reduces the effective tax rate and other expenses. * Improved working capital management, specifically a reduction in the cash conversion cycle. * Stabilization or recovery of investor confidence, which is currently lacking.

3. Main Assumptions: The base case assumes the current pressures on profitability and operational efficiency persist. The bull case is entirely dependent on the successful execution of a major corporate restructuring, for which there is no current evidence.

4. Uncertainty: This forecast carries extremely high uncertainty, as the company's current trajectory suggests a high risk of further significant price declines absent a drastic and immediate reversal of its negative momentum.